ArriVent BioPharma said its clinical trial did not meet the primary endpoint of progression-free survival by blinded independent central review. The company described the results as disappointing. A trend toward improvement in overall survival was observed but is not yet mature.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
